Medicine and Dentistry
Disease
74%
Large-Cell Lymphoma
72%
Non-Hodgkin Lymphoma
62%
B Cell
57%
Acute Myeloid Leukemia
51%
Neoplasm
46%
B-Cell Chronic Lymphocytic Leukemia
41%
Prognostic Factor
41%
Follicular Lymphoma
40%
Tositumomab
39%
Leukemia
39%
Major Histocompatibility Complex
35%
Liposomal Daunorubicin
35%
Monoclonal Antibody Ki 67
35%
Myeloma
31%
CHOP
31%
Rituximab
28%
ABC Transporter Subfamily B
28%
Vincristine Sulfate
28%
Immunophenotyping
27%
Mantle Zone
26%
Lymphoma
26%
Lymphocytic Lymphoma
24%
Iodine 131
23%
Plasma Cell
23%
Progression Free Survival
23%
Antigen Expression
23%
Cyclophosphamide
22%
Prednisone
22%
Immunosurveillance
22%
Overall Survival
22%
Lymphoma Cell
22%
Myeloid Sarcoma
21%
Gene Expression
21%
Lymphoproliferative Disease
20%
T Lymphocyte Antigen
20%
Radioimmunotherapy
20%
T Cell
19%
Multivariate Analysis
19%
Epileptic Absence
17%
Protein Expression
17%
Midline Granuloma
17%
Chromosome Deletion 5
17%
Methylprednisolone
17%
Gemcitabine
17%
Pathologist
17%
Antibody Mediated Rejection
17%
Cell Line
17%
Continuous Infusion
17%
Acute B-Cell Lymphoblastic Leukemia
17%
Immunology and Microbiology
B Cell
100%
Lymphoma Cell
99%
T Cell
93%
Progression Free Survival
48%
Rituximab
46%
Overall Survival
46%
Multiple Myeloma
41%
Cell Line
40%
Tositumomab
39%
HLA-DR
35%
Major Histocompatibility Complex
35%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
27%
Prednisone
26%
Cyclophosphamide
26%
Iodine-131
23%
Tumor Cell
23%
Immunosurveillance
22%
Cytotoxicity
22%
P-Glycoprotein
22%
Multidrug Resistance
22%
Cell Adhesion Molecule
22%
Monospecific Antibody
21%
Arm
21%
Plasma Cell
20%
Antigen Expression
20%
Myeloma Cell Line
20%
Oxidative Stress
17%
Antibody Mediated Rejection
17%
Protein Expression
17%
Melanoma Cell
17%
Immunocompetence
17%
Humoral Immunity
17%
Granuloma
17%
Genetic Polymorphism
17%
Gene Rearrangement
17%
Effector Cell
17%
Receptor Binding
17%
Prevalence
17%
Severe Acute Respiratory Syndrome Coronavirus 2
17%
Stem Cell Factor
17%
Single Nucleotide Polymorphism
17%
Neural Cell Adhesion Molecule
17%
CD56 Antigen
17%
Peripheral T-Cell Lymphoma Not Otherwise Specified
17%
Ibritumomab Tiuxetan
17%
Monoclonal Antibody Ki 67
17%
Sezary Cell
17%
Cell Kinetics
17%
Lactate Dehydrogenase Blood Level
17%
Gene Expression
17%
Keyphrases
Tositumomab
35%
P-glycoprotein (P-gp)
35%
Chemotherapy
35%
Lymphoma
32%
Phase II Study
28%
Follicular Lymphoma
23%
Burkitt
23%
Multidrug-resistant
23%
Involved Field Radiotherapy
22%
Drug Resistance
22%
Doxorubicin
21%
NH4Br
21%
P-glycoprotein Expression
17%
Platinum-etoposide
17%
Tumor Cells
17%
Myeloid Neoplasms
17%
Peripheral T Cells
17%
T-cell non-Hodgkin Lymphoma
17%
MCF-7
17%
Malignant Lymphoma
17%
Lethal Midline Granuloma
17%
Transformed Mycosis Fungoides
17%
Chromosome 5
17%
Gemcitabine
17%
Iodine-131 (131I)
17%
Chronic Antibody-mediated Rejection
17%
Follicular non-Hodgkin Lymphoma
17%
Advanced Malignancies
17%
Cell-to-cell
17%
Resistance Modifier
17%
B Cell Phenotype
17%
Redox
17%
Pediatric Donor
17%
Highly Sensitized
17%
Renal Transplant Outcomes
17%
Intravenous gammaglobulin
17%
Cellular Adhesion Molecules
17%
Lymphoma Therapy
17%
Clinical Drugs
17%
IVIG Therapy
17%
Verapamil
17%
Activated Fibroblasts
17%
Human Botfly
17%
Cutaneous Myiasis
17%
Chemotherapy Alone
17%
Pro-oxidant
17%
Lipid Complex
17%
HLA Expression
17%
Central Nervous System Involvement
17%
Unusual Sites
17%
